Study	Reason for exclusion
Benshushan 2009	Participants in the control group did not have BRCA1/BRCA2 mutation carriers.
Chang‐Claude 2007	Cohort study that assessed breast cancer risk in a large series of 1187 BRCA1 and 414 BRCA2 carriers from the International BRCA1/2 Carrier Cohort Study but included women (1 arm) with a previous or coexisting breast malignancy.
Eisen 2005	Case‐control study that involved 4569 eligible women, of which 2283 women with a BRCA1/2 mutation carriers but included women (1 arm) with a previous or coexisting breast malignancy.
Evans 2009	Although the study was a cohort study that compared the frequency of peritoneal cancers among women receiving risk‐reducing surgery for ovarian cancer, not all the women enrolled were BRCA1 and BRCA2 mutation carriers and none of the included data were complete for extraction in enrolled women with known BRCA1 or BRCA2 mutation status.
Evans 2013	Cohort study that evaluated the incidence of breast cancer after RRM in healthy BRCA mutation carriers, without risk‐reducing BSO.
Finch 2006	Included women with prior history of breast cancer
Finch 2009	Controlled before‐and‐after study with no concurrent comparison groups
Finch 2011	Controlled before‐and‐after study with no concurrent comparison groups
Finch 2013	Controlled before‐and‐after study with no concurrent comparison groups
Finch 2014	Single‐arm cohort study (without comparison group) aimed at estimating the reduction in risk of ovarian, fallopian tube or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the impact of prophylactic oophorectomy on all‐cause mortality; and to estimate 5‐year survival associated with clinically detected ovarian, occult and peritoneal cancers diagnosed in the cohort.
Finkelman 2012	Included women with prior history of breast cancer or ovarian cancer
Heemskerk‐Gerritsen 2013	Cohort study that evaluated the incidence of breast cancer after RRM in healthy BRCA mutation carriers, without risk‐reducing BSO.
Heemskerk‐Gerritsen 2015b	Cohort study that evaluated the incidence of breast cancer after RRM in healthy BRCA mutation carriers, without risk‐reducing BSO.
Hunsinger 2016	Although all the 8 women included in the study were BRCA mutation positive and received prophylactic mastectomy with BSO, there was no control or comparison group. So all women received surgical interventions.
Iavazzo 2016	Review of cases with peritoneal cancer after PBSO and the possible aetiology of the disease as well as the possible changes in the management of such women.
Johansen 2016	Retrospective cohort study of 294 women who underwent RRSO and 1228 women from the normal group aimed at evaluating the sexual pleasure and discomfort scores and frequency of sexual activity using the Sexual Activity Questionnaire. The BRCA1 or BRCA2 mutations status were not specified in any of the women included in the study.
Johansen 2017	Although participants included 324 women after RRSO and 11,160 postmenopausal controls, a subsample of 950 controls had undergone BSO, whose indication for the BSO was not known and the BRCA1 or BRCA2 mutations status of the participants (study group or controls) too, were not reported.
Kauff 2002	Prospective cohort study that compared the effect of RRSO with that of surveillance for ovarian cancer on the incidence of subsequent breast cancer and BRCA related gynaecological cancers in women with BRCA mutations but included women with prior history of breast cancer, with 70% of the salpingo‐oophorectomy group and 62% of the surveillance group having prior history of breast cancer.
Kauff 2008	Prospective cohort study that compared the effect of RRSO with that of surveillance for ovarian cancer on the incidence of subsequent breast cancer and BRCA related gynaecological cancers in women with BRCA mutations but the study included women with prior history of breast cancer in both the RRSO group and the surveillance group.
Kwon 2013	The 2 different comparison groups received bilateral salpingectomy alone or bilateral salpingectomy with delayed oophorectomy. It did not include a control or comparison group of women who carry BRCA1 or BRCA2 mutations and did not receive prophylactic salpingo‐oophorectomy. So all groups received surgical interventions.
Laki 2007	Retrospective study of 89 BRCA1/BRCA2 mutation carriers who underwent BSO. It did not include a control or comparison group of women who carried BRCA1 or BRCA2 mutations and did not receive prophylactic salpingo‐oophorectomy. So all groups received surgical interventions.
Madalinska 2005	Although the study determined the quality of life effects of PBSO versus gynaecologic screening, only 368/846 included women had known BRCA1/2 mutation carriers (265 (72%) women opted for PBSO, and 103 (28%) women, opted for gynaecological screening. Analysis was not based on BRCA1/2 status.
Manchanda 2011	Prospective cohort single‐arm study (without comparison or surveillance group) of women from high‐risk families whose mutation status was unknown, in addition to women who were confirmed BRCA1 or BRCA2 mutation carriers.
Meijers‐Heijboer 2001	Cohort study that evaluated the incidence of breast cancer after RRM in healthy BRCA mutation carriers, without RRSO.
Menkiszak 2016	Cohort study of 195 women who were carriers of 1 of 3 mutations in BRCA1 gene most commonly occurring in the Polish population (5382insC, 4153delA and C61G) subjected to prophylactic salpingo‐oophorectomy. All women underwent prophylactic surgery and there was no comparison group. So all women received surgical interventions.
Metcalfe 2014	Cohort study included 390 women with a family history of stage I or II breast cancer who were carriers of BRCA1 and BRCA2 mutations and initially treated with unilateral or bilateral mastectomy, without bilateral RRSO.
Miller 2017	Retrospective observational cohort study of 70 women that assessed the potential role of peritoneal and omental biopsies in women undergoing RRSO for prophylactic management of hereditary breast/ovarian cancer syndromes. There is a single arm study without a comparison group.
Perabo 2014	Although all 6 women included in the study received prophylactic mastectomy with BSO (4 women had BRCA‐1 mutations, 1 woman had a BRCA‐2 mutation and 1 woman had a family inheritance pattern with no mutations), there was no control or comparison group. So all groups received surgical interventions.
Powell 2011	Single arm study (without comparison group) of 111 women who were carriers of BRCA mutations and had RRSO in order to identify risk factors associated with finding an occult malignancy at RRSO using a rigorous surgical‐pathological protocol.
Rocca 2006	Matched population‐based cohort study that investigated the survival patterns of 2390 women who had received an oophorectomy compared with 2390 women who had not received an oophorectomy but the BRCA1 or BRCA2 mutation status of the participants were not reported.
Rutter 2003	Cohort study that assessed the level and persistence of reduction of ovarian (including peritoneal) cancer risk after gynaecological surgeries for women who carried BRCA1/2 mutations but were not selected from high‐risk clinics but not all women enrolled in the study have known BRCA1/2 mutation status.
Schmeler 2006	Included women with a personal history of breast cancer.
Skytte 2011	Cohort study that evaluated the incidence of breast cancer after RRM in healthy BRCA mutation carriers, without risk‐reducing BSO.
Struewing 1995	Prospective multicentre cohort study that determined the incidence of postoophorectomy carcinomatosis and quantified the effectiveness of preventive surgery, none of the enrolled women had known BRCA1 or BRCA2 mutation status.
van Sprundel 2005	Cohort study included women with a family history or personal history of breast cancer who were carriers of BRCA1 and BRCA2 mutations and initially treated with unilateral or bilateral mastectomy, but without bilateral RRSO.
Vermeulen 2017	Systematic review of implications of premenopausal RRSO on quality of life, endocrine symptoms, sexual function, osteoporosis, cardiovascular health, metabolic syndrome, cognitive impairment and safety of hormone replacement therapy.

BRCA1: breast cancer 1 gene; BRCA2: breast cancer 2 gene; BSO: bilateral salpingo‐oophorectomy; PBSO: prophylactic bilateral salpingo‐oophorectomy; RRM: risk‐reducing mastectomy; RRSO: risk‐reducing salpingo‐oophorectomy.